Agios Pharmaceuticals Inc (STU:8AP)
€ 34.2 -3 (-8.06%) Market Cap: 1.93 Bil Enterprise Value: 1.03 Bil PE Ratio: 3.01 PB Ratio: 1.20 GF Score: 50/100

Agios Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference Transcript

Feb 28, 2019 / 07:00PM GMT
Release Date Price: €56.61 (+2.59%)
Andrew Scott Berens
SVB Leerink LLC, Research Division - MD of Targeted Oncology & Senior Research Analyst

Good evening, everyone. I'm Andrew Berens, Senior Biotech Analyst, Head of Targeted Oncology SVB Leerink, and welcome to the afternoon session in the Holmes Room, Day 2 of our Healthcare Conference. We're pleased to have Agios with us. We have Jacqualyn Fouse and Andrew Hirsch. Thanks for coming in. Appreciate it.

Jacqualyn A. Fouse
Agios Pharmaceuticals, Inc. - CEO & Director

Happy to be here.

Andrew Hirsch
Agios Pharmaceuticals, Inc. - CFO

Thanks for having us.

Andrew Scott Berens;Jacqualyn A. Fouse
SVB Leerink LLC, Research Division - MD of Targeted Oncology & Senior Research Analyst;Agios Pharmaceuticals, Inc. - CEO &

Yes. I just want to give you kudos, Jackie. We've seen other CEOs assume the helm and take several months before they actually get on the stage. So you're jumping in and running. That's great.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot